☆ 4.2 Article

Review of the Emerging Treatment of Clostridium difficile Infection with Fecal Microbiota Transplantation and Insights into Future Challenges

CLINICS IN LABORATORY MEDICINE (2014)

期刊

CLINICS IN LABORATORY MEDICINE

卷 34, 期 4, 页码 787-+

出版社

W B SAUNDERS CO-ELSEVIER INC

DOI: 10.1016/j.cll.2014.08.007

关键词

Clostridium difficile; Health care-associated infections; Fecal microbiota transplantation; Treatment

类别

Medical Laboratory Technology

向作者/读者索取更多资源

Protocol

Reagent

摘要

Clostridium difficile infection (CDI) is one of the most common health care-associated infections in the United States. Currently, there are no standardized methods to prepare or deliver the fecal microbiota transplantation (FMT). Various methods are used to prepare the FMT, which is usually administered via nasogastric tube, colonoscopy, or by enema. Several clinical trials are underway to assess the true efficacy and safety of FMT for CDI. These trials include CDI studies assessing FMT via colonoscopy and frozen encapsulation, fresh versus frozen-and-thawed FMT by enema, FMT compared with a vancomycin taper, and FMT in the pediatric population.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Gastroenterology & Hepatology

Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection

Shaodong Wei, Martin Iain Bahl, Simon Mark Dahl Baunwall, Jens Frederik Dahlerup, Christian Lodberg Hvas, Tine Rask Licht

Summary: This study aimed to explore the relationship between early changes in the intestinal microbiota and clinical outcomes following fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (CDI). The results showed that patients with sustained resolution after FMT had different microbial diversity, abundance, and gut microbiota dysbiosis compared to non-responders. Additionally, a constructed index based on clinically feasible methods successfully predicted treatment failure. It was also found that FMT had a more pronounced impact on the gut microbiota compared to antibiotic monotherapy. Therefore, early identification of microbial community structures after FMT is clinically valuable for predicting treatment response.

GUT MICROBES (2022)

添加到收藏夹

Article Medicine, General & Internal

Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection

Pei-Chang Lee, Tien-En Chang, Yen-Po Wang, Kuei-Chuan Lee, Yi-Tsung Lin, Jen-Jie Chiou, Chi-Wei Huang, Ueng-Cheng Yang, Fen-Yau Li, Hui-Chun Huang, Chun-Ying Wu, Yi-Hsiang Huang, Ming-Chih Hou

Summary: This study aimed to investigate the efficacy of FMT for treating rCDI and its association with microbial changes. The research found that successful FMT was related to treatment outcomes and led to dynamic changes in fecal microbial composition.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Article Biotechnology & Applied Microbiology

The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model

Qiaomai Xu, Shumeng Zhang, Jiazheng Quan, Zhengjie Wu, Silan Gu, Yunbo Chen, Beiwen Zheng, Longxian Lv, Lanjuan Li

Summary: Vancomycin is the preferred treatment for CDI but has a high recurrence rate. FMT has emerged as a successful treatment for recurrent CDI. Our study suggests that FMT can better restore gut microbiota and metabolites, promoting the recovery of colonization resistance in mice compared to vancomycin.

APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2022)

添加到收藏夹

Review Surgery

The evaluation of different types fecal bacteria products for the treatment of recurrent Clostridium difficile associated diarrhea: A systematic review and network meta-analysis

Liping Yang, Wenrui Li, Xianzhuo Zhang, Jinhui Tian, Xiaojia Ma, Lulu Han, Huaping Wei, Wenbo Meng

Summary: This study evaluated the efficacy of different types of fecal microbiota transplantation for the treatment of RCDAD. The results showed that fresh fecal bacteria were the best treatment option, while frozen and lyophilized fecal bacteria had similar effects. Fecal microbiota transplantation is a promising approach for clinical and commercial application.

FRONTIERS IN SURGERY (2022)

添加到收藏夹

Article Immunology

Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection

Elizabeth S. Aby, Byron P. Vaughn, Eva A. Enns, Radha Rajasingham

Summary: This study assessed the cost-effectiveness of fecal microbiota transplantation (FMT) for first recurrent Clostridioides difficile infection (CDI). The findings indicate that FMT is a cost-effective treatment strategy for first recurrent CDI.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Infectious Diseases

Reduction in urinary tract infections in patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection

Raseen Tariq, Pritish. K. K. Tosh, Darrell. S. S. Pardi, Sahil Khanna

Summary: We conducted an updated study to examine the occurrence of urinary tract infections (UTIs) in patients with recurrent Clostridioides difficile infection (CDI) who underwent fecal microbiota transplantation (FMT) for CDI treatment. Our findings revealed a significant decrease in the incidence of UTIs following FMT compared to patients treated with antibiotics for CDI. Furthermore, there was a trend towards reduced antibiotic resistance in UTI-causing organisms after FMT.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Current Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children

Maribeth R. Nicholson, Suchitra K. Hourigan, Maire Conrad, Alka Goyal, Kyle Jensen, Judith Kelsen, Melissa Kennedy, Madison Weatherly, Stacy A. Kahn

Summary: The impact of the 2019 US FDA safety alert and the COVID-19 pandemic on the use of FMT in children has led to changes in practices for many pediatric gastroenterologists, with a majority of programs being halted as a result.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection

Paul Feuerstadt, Thomas J. Louie, Bret Lashner, Elaine E. L. Wang, Liyang Diao, Jessica A. Bryant, Matthew Sims, Colleen S. Kraft, Stuart H. Cohen, Charles S. Berenson, Louis Y. Korman, Christopher B. Ford, Kevin D. Litcofsky, Mary-Jane Lombardo, Jennifer R. Wortman, Henry Wu, John G. Aunins, Christopher W. J. McChalicher, Jonathan A. Winkler, Barbara H. McGovern, Michele Trucksis, Matthew R. Henn, Lisa von Moltke

Summary: SER-109 microbiome therapy is superior to placebo in reducing the risk of recurrent C. difficile infection, and has a similar safety profile as placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections

Colleen R. Kelly, Monika Fischer, Jessica R. Allegretti, Kerry LaPlante, David B. Stewart, Berkeley N. Limketkai, Neil H. Stollman

Summary: This article discusses the causes and management of Clostridioides difficile infection, as well as the official practice recommendations of the American College of Gastroenterology. The guidelines were evaluated using the Grading of Recommendations Assessment, Development, and Evaluation process.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Fecal Microbiota Transplantation and Medical Therapy for Clostridium difficile Infection Meta-analysis of Randomized Controlled Trials

Tanveer Singh, Prabhjot Bedi, Karandeep Bumrah, Darshan Gandhi, Tanureet Arora, Nikita Verma, Mary Schleicher, Manoj P. Rai, Rajat Garg, Beni Verma, Madhusudhan R. Sanaka

Summary: Fecal microbiota transplantation (FMT) is effective in the treatment of recurrent Clostridium difficile infection (CDI), but not significant in primary CDI.

JOURNAL OF CLINICAL GASTROENTEROLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls

Avnish Sandhu, Teena Chopra

Summary: Clostridioides difficile infection (CDI) is a major cause of hospital-acquired infections, with recurrent CDI (rCDI) posing a challenge in treatment. Fecal microbiota transplantation (FMT) is suggested for second episodes of rCDI, showing promise compared to traditional treatments like vancomycin or fidaxomicin. However, concerns over infections, adverse events, and new diagnoses remain, requiring further study for long-term safety and efficacy of FMT in clinical practice.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Faecal microbiota transplantation: what's beyond Clostridium difficile infection?

Aravind Gokul Tamilarasan, Thanuja Krishnananthan

Summary: In recent years, significant progress has been made in the study of the intestinal microbiota, with research moving beyond the laboratory and into clinical applications like fecal microbiota transplantation. Studies have shown interesting associations between imbalances in the intestinal microbiota and disease development, highlighting the potential therapeutic benefits of fecal microbiota transplantation in reversing this process.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Fecal microbiota transplantation and Clostridioides difficile infection among privately insured patients in the United States

Jessica El Halabi, Nathan Palmer, Kathe Fox, Isaac Kohane, Maha R. Farhat

Summary: This study found that the cases of CDI in the US have been increasing over the past decade, with a changing treatment landscape due to the adoption of FMT. FMT is strongly associated with a decrease in CDI recurrence compared to anti-CDI antibiotics, with potential gastrointestinal complications and sepsis in the short term post FMT.

JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection

Olle Bjorkqvist, Ignacio Rangel, Lena Serrander, Cecilia Magnusson, Jonas Halfvarson, Torbjorn Noren, Malin Bergman-Jungestrom

Summary: The study found that FMT can increase the relative abundance of Faecalibacterium prausnitzii in patients with recurrent CDI, and this microbial shift persists for several months later. Further research is needed to determine whether Faecalibacterium prausnitzii actively contributes to the resolution of CDI.

PLOS ONE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical effectiveness of bidirectional fecal microbiota transfer in the treatment of recurrent Clostridioides difficile infections

Christian Bestfater, Maria J. G. T. Vehreschild, Andreas Stallmach, Kester Tueffers, Andreas Erhardt, Thorsten Frank, Thomas Glueck, Felix Goeser, Gernot Sellge, Philipp Solbach, Herbert Eisenlohr, Martin Storr

Summary: Simultaneous bidirectional FMT showed superior primary cure rates compared to standard unidirectional approaches for recurrent Clostridioides difficile infection, highlighting the importance of treatment route in optimizing patient outcomes. Further prospective studies are needed to confirm these findings.

DIGESTIVE AND LIVER DISEASE (2021)

添加到收藏夹

暂无数据

暂无数据

© Peeref 2019-2024. All rights reserved.